BioSpace News Archive

BioStem Technologies Inc. announced that the United States Patent and Trademark Office has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914.

Congruence Therapeutics, a leading computationally-driven biotechnology company developing a pipeline of novel small molecules for diseases with significant unmet medical need, announced the appointment of Michael D. Harvey, Ph.D. as Chief Development Officer.

Regulus Therapeutics Inc. today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months.

The method, invented by University of Birmingham scientists and patented by University of Birmingham Enterprise, delivers light directly to the site of the injury.

Ratio Therapeutics Inc. today announced the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer.

Allegria Therapeutics, a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced a Seed Financing of USD 3.5 Million by founding investor Forty51 Ventures.

Boundless Bio today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will present at the Citizens JMP Life Sciences Conference 2024.

OpRegen ® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit.

Phonak today announces an FDA cleared self-replacement option for Phonak Lyric, the world’s only 100% invisible hearing aid that provides 24/7 hassle-free hearing with proven tinnitus relief.

Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.